Cargando…

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes

Type 2 diabetes is characterized by a progressive decline in beta cell function, with consequent worsening of glycemic control. The ideal antihyperglycemic treatment should achieve good and sustained glycemic control, with a low risk of hypoglycemia and no weight gain. This paper reviews the efficac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rigato, Mauro, Fadini, Gian Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964023/ https://www.ncbi.nlm.nih.gov/pubmed/24672252 http://dx.doi.org/10.2147/DMSO.S37644

Ejemplares similares

Fixed versus flexible combination of GLP‐1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study
por: Morieri, Mario Luca, et al.
Publicado: (2019)

Potential of liraglutide in the treatment of patients with type 2 diabetes
por: Deacon, Carolyn F
Publicado: (2009)

Liraglutide in the management of type 2 diabetes
por: Wajcberg, Estela, et al.
Publicado: (2010)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Effectiveness of remote screening for diabetic retinopathy among patients referred to Mozambican Diabetes Association (AMODIA): a retrospective observational study
por: Rigato, Mauro, et al.
Publicado: (2022)

Comparative effectiveness of exenatide once‐weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta‐analysis of observational studies
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives
por: Edavalath, Mahamood, et al.
Publicado: (2010)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Neumiller, Joshua J, et al.
Publicado: (2010)

Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs
por: Sjöholm, Åke
Publicado: (2010)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
por: Jacobsen, Lisbeth V., et al.
Publicado: (2015)

Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
por: Seo, Young-Gyun
Publicado: (2021)

Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review
por: Ostawal, Amrita, et al.
Publicado: (2016)

Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide
por: Ghosh, Aneesh
Publicado: (2021)

Effect of liraglutide on expression of inflammatory genes in type 2 diabetes
por: Zobel, Emilie H., et al.
Publicado: (2021)

The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes
por: Zhao, Na, et al.
Publicado: (2021)

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
por: Gough, Stephen CL, et al.
Publicado: (2016)

Stem cell mobilization with plerixafor and healing of diabetic ischemic wounds: A phase IIa, randomized, double‐blind, placebo‐controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes
por: Wu, Hao, et al.
Publicado: (2023)

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
por: Minze, Molly G, et al.
Publicado: (2016)

Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients
por: Zameer, Rafia, et al.
Publicado: (2020)

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
por: Sivalingam, Suvanjaa, et al.
Publicado: (2021)

It Is All in the Blood: The Multifaceted Contribution of Circulating Progenitor Cells in Diabetic Complications
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Managing diabetes in diabetic patients with COVID: where do we start from?
por: Avogaro, Angelo, et al.
Publicado: (2021)

Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2019)

Clinical and psychological characteristics of liraglutide treatment among patients with type 2 diabetes
por: Al Hayek, Ayman A., et al.
Publicado: (2020)

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes
por: Su, Yu, et al.
Publicado: (2023)

Impaired Hematopoietic Stem/Progenitor Cell Traffic and Multi-organ Damage in Diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2022)

Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
por: Yabe, Daisuke, et al.
Publicado: (2011)

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
por: Nauck, Michael, et al.
Publicado: (2009)

Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
por: Vega-Hernandez, Gabriela, et al.
Publicado: (2017)

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment
por: Zobel, Emilie H., et al.
Publicado: (2019)

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
por: Ohki, Takamasa, et al.
Publicado: (2012)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
por: Howell, Rebecca, et al.
Publicado: (2019)

Liraglutide Treatment in a Patient With HIV and Uncontrolled Insulin-Treated Type 2 Diabetes
por: Diamant, Michaela, et al.
Publicado: (2012)

Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting
por: Simioni, N., et al.
Publicado: (2018)

Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment
por: Rafiullah, Mohamed, et al.
Publicado: (2023)

Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study
por: Fadini, Gian Paolo, et al.
Publicado: (2020)

The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
por: Ehlers, Lars Holger, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_34v4lmov3rvghcmujb5b5ef6tn